INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Lantheus Holdings, Inc. - LNTH

Core Insights - Lantheus Holdings, Inc. is under investigation for potential securities fraud and unlawful business practices [1] - The company reported disappointing Q2 2025 results, with earnings-per-share and revenue figures missing expectations [3] - Lantheus lowered its full year 2025 revenue guidance from $1.550 billion - $1.585 billion to $1.475 billion - $1.51 billion, and adjusted EPS guidance from $6.60 - $6.70 to $5.50 - $5.70 [3] - The company's consolidated net revenue for Q2 was $378 million, a decrease of 4.1%, with PYLARIFY sales down 8.3% to $250.6 million [3] - Following the earnings announcement, Lantheus's stock price fell by $20.76, or 28.58%, closing at $51.87 [3] Company Overview - Lantheus Holdings, Inc. operates in the radiopharmaceutical oncology sector, specifically in the PSMA PET market [3] - The CEO indicated a strategic decision to reduce volume at certain accounts to protect long-term franchise value amid pricing pressures [3] Legal Context - Pomerantz LLP is leading the investigation on behalf of investors, highlighting the firm's expertise in corporate and securities class litigation [1][4] - The firm has a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [4]